New combo therapy aims to stall hard-to-treat colon cancer

NCT ID NCT04963283

Ongoing Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Feb 11, 2026 · Last updated May 23, 2026 · Updated 17 times

Summary

This study tests a two-drug combination (cabozantinib and nivolumab) in people with advanced colorectal cancer that is microsatellite stable (MSS) and has stopped responding to standard treatments. The goal is to see if the combination can control the cancer for at least 16 weeks. About 48 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

UCHealth Family Medicine - Greeley

Greeley, Colorado, 80634, United States
UCHealth Harmony Campus

Fort Collins, Colorado, 80528, United States
UCHealth Medical Center of the Rockies

Loveland, Colorado, 80538, United States
UCHealth Memorial Hospital Central

Colorado Springs, Colorado, 80909, United States
University of Colorado Hospital

Aurora, Colorado, 80012, United States

Conditions

Explore the condition pages connected to this study.

COLON ADENOCARCINOMA COLON ADENOCARCINOMA COLON CANCER COLON CANCER COLORECTAL ADENOCARCINOMA COLORECTAL ADENOCARCINOMA COLORECTAL CANCER RECTAL ADENOCARCINOMA RECTAL CANCER RECTUM CANCER